The global Non-Hodgkin lymphoma treatment market is anticipated to grow at a significant CAGR during the forecast period. The Non-Hodgkin lymphoma cancer is more common with high prevalence which will drive the Non-Hodgkin lymphoma treatment industry considerably. Non-Hodgkin lymphoma shows constitutional symptoms as well as hepatosplenomegaly symptoms. Constitutional symptoms include weight loss, hyperhidrosis, generalized hyperhidrosis, chronic pain, fatigue, and malaise. Whereas hepatosplenomegaly symptoms include abdominal pain, swelling or tenderness, nausea and vomiting, fever.
Browse the full report description of "Global Non-Hodgkin lymphoma treatment Market Size, Share & Trends Analysis Report By Cell Type (B-Cell and T-Cell), By Therapy Type (Chemotherapy, Radiation Therapy, and Others), and Forecast 2019-2025" at https://www.omrglobal.com/industry-reports/non-hodgkin-lymphoma-reatment-market
Some lymphomas will secrete Immunoglobulin M (IgM) which leads to hyperviscosity syndrome as well as autoimmune cytopenia. Hence, rise in autoimmune diseases across the globe will significantly drive the Non-Hodgkin lymphoma treatment market. The non-Hodgkin lymphomas also secrete gammaglobulinemia which leads to infectious diseases. Thus, the increasing infection will also drive the market.
Additionally, Non-Hodgkin lymphoma is the second most common cancer in patients with AIDS. According to the World Health Organization, 37.9 million people are living with HIV in 2018 across the globe. People living with HIV are about ten times more likely to develop Non-Hodgkin lymphoma than people without HIV. Hence the increasing AIDS cases across the globe is likely to drive the Non-Hodgkin lymphoma treatment market significantly.
Moreover, the risk of developing Non-Hodgkin lymphoma is significantly high after organ transplant as the patient’s immunity becomes weak after the transplantation. Therefore, the increase in organ transplantation activities will also fuel the Non-Hodgkin lymphoma treatment market. In addition to this, immunosuppressed as well as congenital immune deficiency patients are also at high risk of developing Non-Hodgkin lymphoma. Hence, the patient pool of these kind of diseases will significantly impact the Non-Hodgkin lymphoma treatment industry size.
Additionally, the increasing use of radiation and chemotherapy as the first line of treatment in lymphoma cancer will also impact the Non-Hodgkin lymphoma treatment market growth. Besides, the development and advancements of therapies such as CAR-T cells are also anticipated to drive the market during the forecast period.
Global Non-Hodgkin Lymphoma Treatment Market- Segmentation
By Cell Type
By Therapy Type
Global Non-Hodgkin Lymphoma Treatment Market- Segment by Region
North America
Europe
Asia-Pacific
Rest of the World